+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market by Drug, and Type: Global Opportunity Analysis and Industry Forecast, 2019-2026

  • ID: 4828623
  • Report
  • Region: Global
  • 113 pages
  • Allied Analytics LLP
1 of 3
The global acute lymphocytic/lymphoblastic leukemia therapeutics market accounted for $2,334.5 million in 2018, and is expected to reach $3,528.8 million by 2026, registering a CAGR of 5.3% from 2019 to 2026.

There has been a steady rise in the incidences of acute lymphoblastic leukemia (ALL) and the number of bone marrow biopsies across the world. Moreover, focus on R&D of leukemia therapeutics has been increased. These factors drive the growth of the acute lymphocytic/lymphoblastic leukemia therapeutics market. However, stringent regulatory paths for approvals of the therapeutics as well as the adverse side effects associated with these drugs restrict the growth of the global market. Nevertheless, the rise in number of clinical trials and new product approvals are anticipated to create newer opportunities in the emerging as well as the developed markets.

The acute lymphocytic/lymphoblastic leukemia therapeutics market has gained prominence in the recent years due to high prevalence of ALL worldwide and as a result, there is an increase in the need for leukemia diagnosis. Furthermore, growth potential offered by developing economies, increase in investment in the R&D of different leukemia, and rise in awareness of targeted therapies amongst the population present lucrative opportunities during the forecast period. However, patent expiry of the blockbuster drugs used in the treatment and higher costs involved in the therapies are expected to restrain the market growth.

The acute lymphocytic/lymphoblastic leukemia therapeutics market is segmented based on drugs, type, and region to provide a detailed assessment of the market. Based on drug, the market is divided into Hyper-CVAD Regimen, Linker Regimen, Nucleoside Metabolic Inhibitors (Clolar and Nelarabine), Targeted Drugs & Immunotherapy, CALGB 8811 Regimen, and Oncaspar. Based on type, the market is classified into pediatrics and adults. Based on region, the acute lymphocytic/lymphoblastic leukemia therapeutics market size is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS
  • The study provides an in-depth analysis of the global acute lymphocytic/lymphoblastic leukemia therapeutics market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • The report presents a quantitative analysis of the market from 2018 to 2026 to enable stakeholders to capitalize on the prevailing market opportunities.
  • An extensive analysis of the market based on application assists in understanding the trends in the industry.
  • The key market players along with their strategies are thoroughly analyzed to understand the competitive outlook of the industry.
KEY MARKET SEGMENTS
  • By Type
o Pediatrics
o Adults
  • By Drug
o Hyper-CVAD Regimen
o Linker Regimen
o Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)
o Targeted Drugs & Immunotherapy
o CALGB 8811 Regimen
o Oncaspar
  • By Region
o North America
o Europe
o Asia-Pacific
o LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • Amgen, Inc.
  • Bristol-Myers Squibb Company
  • Erytech Pharma
  • Leadiant Biosciences, Inc. (Sigma-Tau Pharmaceuticals Inc.)
  • Novartis AG, Pfizer, Inc.
  • Rare Disease Therapeutics, Inc.
  • Sanofi
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
Note: Product cover images may vary from those shown
2 of 3
CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits to Stakeholders
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. Porters five forces analysis

3.3.1. Bargaining power of suppliers
3.3.2. Threat of new entrants
3.3.3. Threat of substitutes
3.3.4. Competitive rivalry
3.3.5. Bargaining power among buyers

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Rise in the Incidences of Acute Lymphoblastic Leukemia
3.4.1.2. Rise in Number of New Product Approvals

3.4.2. Restraints

3.4.2.1. Patent Expiry of Blockbuster Drugs
3.4.2.2. Side effects of the treatment

3.4.3. Opportunity

3.4.3.1. Increase in number of Clinical Trials

CHAPTER 4: ACUTE LYMPHOCYTIC LEUKEMIA MARKET, BY TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Pediatric

4.2.1. Market size and forecast

4.3. Adult

4.3.1. Market size and forecast

CHAPTER 5: ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG

5.1. Overvie

5.1.1. Market size and forecast

5.2. Hyper-CVAD regimen

5.2.1. Market size and forecast

5.3. Linker regimen

5.3.1. Market size and forecast

5.4. Nucleoside metabolic inhibitors (Clolar and Nelarabine)

5.4.1. Market size and forecast

5.5. Targeted drugs & immunotherapy

5.5.1. Market size and forecast

5.6. CALGB 8811 regimen

5.6.1. Market size and forecast

5.7. Oncaspar

5.7.1. Market size and forecast

CHAPTER 6: ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends and opportunities

6.3. Europe

6.3.1. Key market trends and opportunities

6.4. Asia-Pacific

6.4.1. Key market trends and opportunities

6.5. LAMEA

6.5.1. Key market trends and opportunities

CHAPTER 7: COMPANY PROFILES

7.1. AMGEN, INC

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments

7.2. BRISTOL-MYERS SQUIBB COMPANY

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments

7.3. ERYTECH PHARMA

7.3.1. Company overview
7.3.2. Operating business segments
7.3.3. Product portfolio
7.3.4. Key strategic moves and developments

7.4. LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.)

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio

7.5. NOVARTIS AG

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments

7.6. PFIZER, INC

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments

7.7. RARE DISEASE THERAPEUTICS, INC.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio

7.8. SANOFI

7.8.1. Company overview
7.8.2. Operating business segments
7.8.3. Product portfolio
7.8.4. Business performance

7.9. SPECTRUM PHARMACEUTICALS, INC

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments

7.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED

7.10.1. Company overview
7.10.2. Operating business segments
7.10.3. Product portfolio
7.10.4. Key strategic moves and developments

*Full List of Tables and Figures Available on Enquiry.

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll